<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363297</url>
  </required_header>
  <id_info>
    <org_study_id>B1931010</org_study_id>
    <secondary_id>3129K6-1106</secondary_id>
    <nct_id>NCT01363297</nct_id>
  </id_info>
  <brief_title>Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia</brief_title>
  <official_title>An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 1 portion of this study will assess the safety, tolerability and efficacy at
      increasing dose levels of inotuzumab ozogamicin in subjects with CD22-positive relapsed or
      refractory adult acute lymphocytic leukemia (ALL) in order to select the recommended phase 2
      dose (RP2D) and schedule. The Phase 2 portion of the study will evaluate the efficacy of
      inotuzumab ozogamicin as measured by hematologic remission rate (CR + CRi) in patients in
      second or later salvage status.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Dose Limiting Toxicities (DLTs) During the Phase 1 Dose-Finding Phase</measure>
    <time_frame>Cycle 1</time_frame>
    <description>DLT was any of the following in the first cycle &amp; attributable to inotuzumab ozogamicin: any greater than or equal to (≥) Grade 4 non-hematologic toxicity except nausea/vomiting (if manageable with supportive care), alopecia, &amp; toxicities secondary to neutropenia &amp; sepsis; prolonged myelosuppression (absolute neutrophil count [ANC] less than [&lt;] 500 per microliter [/µL] or platelet count &lt;25,000/µL in bone marrow with &lt;5 percent (%) blasts &amp; no evidence of leukemia more than 45 days beyond the most recent dose of test article); any Grade 3 non-hematologic toxicity (excluding toxicities such as alopecia or those secondary to neutropenia &amp; sepsis) not resolving to ≥ Grade 2 within 7 days of the most recent dose of test article or was clinically significant irrespective of duration; any ≥ Grade 3 elevation of alanine aminotransferase, aspartate aminotransferase or bilirubin lasting ≥7 days; any test article related toxicity resulting in permanent discontinuation of test article.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Preliminary Satisfactory Response (Complete Response [CR], CR With Incomplete Count Recovery [CRi], Partial Response [PR], or Resistant Disease [RD]) Indicating Disease Stability After First Dose During Phase 1 Dose-Finding</measure>
    <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
    <description>CR was the disappearance of leukemia indicated by &lt;5% marrow blasts and absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was as for CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was an improved or no worsening of acute lymphocytic leukemia indicated by no peripheral blood blasts, and/or at least a 50% decrease in the marrow blast percentage, compared to pre-treatment value, and marrow blast percentage ≥5% and less than or equal to (≤)25% and/or C2 extramedullary disease status. RD occurred if a participant survived ≥7 days following completion of initial treatment course and had persistent leukemia in the most recent peripheral blood smear or bone marrow and/or persistent disease involvement at any extramedullary site after completion of therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With CR or CRi During Phase 2</measure>
    <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
    <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With CR, CRi or PR During the Phase 1 Expansion Phase</measure>
    <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
    <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CR, CRi or PR in Phase 2</measure>
    <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
    <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Minimal Residual Disease (MRD) Negativity in Participants Achieving CR and CRi</measure>
    <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
    <description>MRD negativity was defined as &lt;0.01% mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CR or CRi by Cytogenetic Category</measure>
    <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
    <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had a Post-Treatment Stem-Cell Transplant (SCT)</measure>
    <time_frame>Up to approximately 2 years from first dose</time_frame>
    <description>Post-treatment SCT rate was defined as the percentage of participants who underwent SCT following treatment with inotuzumab ozogamicin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years from first dose</time_frame>
    <description>PFS was defined as the time from Cycle 1 Day 1 to first documentation of PFS event (earliest date of objective progression [PD], treatment discontinuation due to global deterioration of health status, subsequent induction or transplant after best response of PR or resistant disease, relapse after CR or CRi, or death due to any cause). Participants last known to be 1) alive and 2) without a PFS event, were censored at the date of the last disease assessment that verified lack of event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Remission (DoR1) for Participants Who Achieved CR or CRi</measure>
    <time_frame>Up to approximately 2 years from first dose</time_frame>
    <description>DoR1 was defined for participants who responded as the time from the date of first documentation of Complete Hematologic Response (CR or CRi) to the date of the first documentation of relapse after CR or CRi, treatment discontinuation due to global deterioration of health status) or to death due to any cause. Participants last known to be 1) alive and 2) without a DoR1 event, were censored at the date of the last disease assessment that verified lack of event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) for Participants Who Achieved CR/CRi or PR</measure>
    <time_frame>Up to approximately 2 years from first dose</time_frame>
    <description>DoR was defined for participants who respond as the time from the date of first documentation of Hematologic Response (CR, CRi, or PR) to the date of the first documentation of DoR event (earliest date of PD, treatment discontinuation due to global deterioration of health status, first induction therapy or transplant after PR, relapse after CR or CRi or death due to any cause). Participants last known to be 1) alive and 2) without a DoR event, were censored at the date of the last disease assessment that verified lack of event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2 years from first dose</time_frame>
    <description>OS was defined as the time from Cycle 1 Day 1 to date of death due to any cause. If death was not documented, censoring occurred at the date at which the participant was last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Remission for Participants Who Achieved CR or CRi</measure>
    <time_frame>Up to approximately 2 years from first dose</time_frame>
    <description>Time to remission was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic remission (CR or CRi) in participants achieving remission during study therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response for Participants Who Achieved CR/CRi or PR</measure>
    <time_frame>Up to approximately 2 years from first dose</time_frame>
    <description>Time to response was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic response (CR, CRi, or PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to MRD Negativity for Participants Who Achieved CR or CRi</measure>
    <time_frame>Screening, Day 21 of Cycles 1 to 6 and up to 4 to 6 weeks after the last dose (up to 34 weeks)</time_frame>
    <description>Time to MRD negativity was defined as the time from the date of first dose of study drug to the date of first documentation of MRD negativity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Follow-Up</measure>
    <time_frame>From first dose up to approximately 2 years</time_frame>
    <description>Duration of follow-up was defined as the time from the date of first dose of study drug to the date of last contact for participants known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Cluster of Differentiation-22 Positive (CD22+) Leukemic Blasts in Abnormal B Cells in Blood by Visit</measure>
    <time_frame>Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4</time_frame>
    <description>CD22+ leukemic blasts assessed in abnormal B cells from blood (data from central laboratories only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD22+ Leukemic Blasts in Abnormal B Cells in Bone Marrow by Visit</measure>
    <time_frame>Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4</time_frame>
    <description>CD22+ leukemic blasts assessed in abnormal B cells from bone marrow (data from central laboratories only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Messenger Ribonucleic Acid (mRNA) Gene Expression</measure>
    <time_frame>Predose and postdose on Days 1 and 15 of Cycle 1</time_frame>
    <description>Optional blood samples for pharmacogenomic parameters were collected during Cycle 1 prior to the start of the inotuzumab ozogamicin infusion (0 hours) and 1 hour post-dose (original Final Protocol and Protocol Amendments 1 and 2) or 3 hours post-dose (Protocol Amendments 3 and 4) on Day 1 and Day 15 from those participants who provided consent. Gene expression analysis of samples collected pre- and post-dosing was performed using 96-gene TaqMan® low density array cards to examine the concordance between clinical outcome and expression of genes such as those involved in DNA damage response, apoptosis, B-cell antigen expression, glutathione metabolism, drug transport and the phosphoinositide 3-kinase/mammalian target of rapamycin pathway. Expression for each gene was reported as a normalized value, 2^-change in (∆) threshold cycle (Ct), where ∆Ct is Ct^target gene minus Ct^reference genes, averaged.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Acute Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Inotuzumab Ozogamicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotuzumab Ozogamicin</intervention_name>
    <description>Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m^2 to 2.0 mg/m^2.
Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m^2.</description>
    <arm_group_label>Inotuzumab Ozogamicin</arm_group_label>
    <other_name>CMC-544</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with CD22-positive ALL with either refractory disease (i.e. disease
             progression or no response while receiving their most recent prior anti-cancer
             therapy), or relapsed disease (i.e. response to their most recent prior anti-cancer
             therapy with subsequent relapse). Subjects enrolled in the Phase 2 portion of the
             study must be due to receive salvage 2 or later therapy.

          -  Subjects with Philadelphia chromosome-positive (Ph+) ALL must have failed standard
             treatment with at least one tyrosine kinase inhibitor.

          -  Adequate renal and hepatic function, and negative pregnancy test for women of
             childbearing potential.

        Exclusion Criteria:

          -  Subjects with isolated extramedullary relapse or active central nervous system (CNS)
             leukemia.

          -  Prior allogeneic hematopoietic stem cell transplant (HSCT) or other anti-CD22
             immunotherapy within 4 months, or active graft versus host disease (GvHD) at study
             entry.

          -  Evidence or history of veno-occlusive disease (VOD) or sinusoidal obstruction syndrome
             (SOS).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Unversity Cancer Clinical Trials Office</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Unversity Hospital and Clinics, CTRU</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital (BWH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute at Farmington Hills</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1931010&amp;StudyName=Study%20Evaluating%20Inotuzumab%20Ozogamicin%20In%20Acute%20Lymphocytic%20Leukemia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2011</study_first_posted>
  <results_first_submitted>August 25, 2015</results_first_submitted>
  <results_first_submitted_qc>March 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2017</results_first_posted>
  <disposition_first_submitted>July 31, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 31, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 21, 2015</disposition_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/Refractory Acute Lymphocytic Leukemia (ALL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="P2">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="P3">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="P4">
          <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="P5">
          <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set - included all enrolled participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="B2">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="B3">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="B4">
          <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="B5">
          <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="35"/>
            <count group_id="B6" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="1.53"/>
                    <measurement group_id="B2" value="44.9" spread="18.06"/>
                    <measurement group_id="B3" value="43.1" spread="18.37"/>
                    <measurement group_id="B4" value="53.4" spread="13.82"/>
                    <measurement group_id="B5" value="40.7" spread="17.08"/>
                    <measurement group_id="B6" value="44.9" spread="17.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Dose Limiting Toxicities (DLTs) During the Phase 1 Dose-Finding Phase</title>
        <description>DLT was any of the following in the first cycle &amp; attributable to inotuzumab ozogamicin: any greater than or equal to (≥) Grade 4 non-hematologic toxicity except nausea/vomiting (if manageable with supportive care), alopecia, &amp; toxicities secondary to neutropenia &amp; sepsis; prolonged myelosuppression (absolute neutrophil count [ANC] less than [&lt;] 500 per microliter [/µL] or platelet count &lt;25,000/µL in bone marrow with &lt;5 percent (%) blasts &amp; no evidence of leukemia more than 45 days beyond the most recent dose of test article); any Grade 3 non-hematologic toxicity (excluding toxicities such as alopecia or those secondary to neutropenia &amp; sepsis) not resolving to ≥ Grade 2 within 7 days of the most recent dose of test article or was clinically significant irrespective of duration; any ≥ Grade 3 elevation of alanine aminotransferase, aspartate aminotransferase or bilirubin lasting ≥7 days; any test article related toxicity resulting in permanent discontinuation of test article.</description>
        <time_frame>Cycle 1</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Dose Limiting Toxicities (DLTs) During the Phase 1 Dose-Finding Phase</title>
          <description>DLT was any of the following in the first cycle &amp; attributable to inotuzumab ozogamicin: any greater than or equal to (≥) Grade 4 non-hematologic toxicity except nausea/vomiting (if manageable with supportive care), alopecia, &amp; toxicities secondary to neutropenia &amp; sepsis; prolonged myelosuppression (absolute neutrophil count [ANC] less than [&lt;] 500 per microliter [/µL] or platelet count &lt;25,000/µL in bone marrow with &lt;5 percent (%) blasts &amp; no evidence of leukemia more than 45 days beyond the most recent dose of test article); any Grade 3 non-hematologic toxicity (excluding toxicities such as alopecia or those secondary to neutropenia &amp; sepsis) not resolving to ≥ Grade 2 within 7 days of the most recent dose of test article or was clinically significant irrespective of duration; any ≥ Grade 3 elevation of alanine aminotransferase, aspartate aminotransferase or bilirubin lasting ≥7 days; any test article related toxicity resulting in permanent discontinuation of test article.</description>
          <population>Safety analysis set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Preliminary Satisfactory Response (Complete Response [CR], CR With Incomplete Count Recovery [CRi], Partial Response [PR], or Resistant Disease [RD]) Indicating Disease Stability After First Dose During Phase 1 Dose-Finding</title>
        <description>CR was the disappearance of leukemia indicated by &lt;5% marrow blasts and absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was as for CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was an improved or no worsening of acute lymphocytic leukemia indicated by no peripheral blood blasts, and/or at least a 50% decrease in the marrow blast percentage, compared to pre-treatment value, and marrow blast percentage ≥5% and less than or equal to (≤)25% and/or C2 extramedullary disease status. RD occurred if a participant survived ≥7 days following completion of initial treatment course and had persistent leukemia in the most recent peripheral blood smear or bone marrow and/or persistent disease involvement at any extramedullary site after completion of therapy.</description>
        <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Preliminary Satisfactory Response (Complete Response [CR], CR With Incomplete Count Recovery [CRi], Partial Response [PR], or Resistant Disease [RD]) Indicating Disease Stability After First Dose During Phase 1 Dose-Finding</title>
          <description>CR was the disappearance of leukemia indicated by &lt;5% marrow blasts and absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was as for CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was an improved or no worsening of acute lymphocytic leukemia indicated by no peripheral blood blasts, and/or at least a 50% decrease in the marrow blast percentage, compared to pre-treatment value, and marrow blast percentage ≥5% and less than or equal to (≤)25% and/or C2 extramedullary disease status. RD occurred if a participant survived ≥7 days following completion of initial treatment course and had persistent leukemia in the most recent peripheral blood smear or bone marrow and/or persistent disease involvement at any extramedullary site after completion of therapy.</description>
          <population>Safety analysis set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With CR or CRi During Phase 2</title>
        <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL.</description>
        <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CR or CRi During Phase 2</title>
          <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL.</description>
          <population>Safety analysis set</population>
          <units>Percentage of Partcicipants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="53.39" upper_limit="81.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With CR, CRi or PR During the Phase 1 Expansion Phase</title>
        <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.</description>
        <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CR, CRi or PR During the Phase 1 Expansion Phase</title>
          <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.</description>
          <population>Safety analysis set</population>
          <units>Percentage of Partcicipants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" lower_limit="19.22" upper_limit="74.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CR, CRi or PR in Phase 2</title>
        <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.</description>
        <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CR, CRi or PR in Phase 2</title>
          <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.</description>
          <population>Safety analysis set</population>
          <units>Percentage of Partcicipants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" lower_limit="56.74" upper_limit="87.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Minimal Residual Disease (MRD) Negativity in Participants Achieving CR and CRi</title>
        <description>MRD negativity was defined as &lt;0.01% mononuclear cells.</description>
        <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
        <population>Number of participants who achieved CR and CRi</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Minimal Residual Disease (MRD) Negativity in Participants Achieving CR and CRi</title>
          <description>MRD negativity was defined as &lt;0.01% mononuclear cells.</description>
          <population>Number of participants who achieved CR and CRi</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CR or CRi by Cytogenetic Category</title>
        <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL.</description>
        <time_frame>From screening to progressive disease or another induction therapy started, up to approximately 2 years</time_frame>
        <population>Safety analysis set (n refers to number of participants evaluated)</population>
        <group_list>
          <group group_id="O1">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CR or CRi by Cytogenetic Category</title>
          <description>CR was defined as a disappearance of leukemia as indicated by &lt;5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC &lt;1000/µL and/or platelets &lt;100,000/µL.</description>
          <population>Safety analysis set (n refers to number of participants evaluated)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ph+ (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had a Post-Treatment Stem-Cell Transplant (SCT)</title>
        <description>Post-treatment SCT rate was defined as the percentage of participants who underwent SCT following treatment with inotuzumab ozogamicin.</description>
        <time_frame>Up to approximately 2 years from first dose</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had a Post-Treatment Stem-Cell Transplant (SCT)</title>
          <description>Post-treatment SCT rate was defined as the percentage of participants who underwent SCT following treatment with inotuzumab ozogamicin.</description>
          <population>Safety analysis set</population>
          <units>Percentage of Particicpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="22.9"/>
                    <measurement group_id="O6" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time from Cycle 1 Day 1 to first documentation of PFS event (earliest date of objective progression [PD], treatment discontinuation due to global deterioration of health status, subsequent induction or transplant after best response of PR or resistant disease, relapse after CR or CRi, or death due to any cause). Participants last known to be 1) alive and 2) without a PFS event, were censored at the date of the last disease assessment that verified lack of event.</description>
        <time_frame>Up to approximately 2 years from first dose</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time from Cycle 1 Day 1 to first documentation of PFS event (earliest date of objective progression [PD], treatment discontinuation due to global deterioration of health status, subsequent induction or transplant after best response of PR or resistant disease, relapse after CR or CRi, or death due to any cause). Participants last known to be 1) alive and 2) without a PFS event, were censored at the date of the last disease assessment that verified lack of event.</description>
          <population>Safety analysis set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2.1" upper_limit="6.4"/>
                    <measurement group_id="O2" value="NA" lower_limit="1.4">Median and upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O3" value="8.8" lower_limit="1.3" upper_limit="16.7"/>
                    <measurement group_id="O4" value="1.9" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="3.7" lower_limit="2.6" upper_limit="4.7"/>
                    <measurement group_id="O6" value="3.9" lower_limit="3.0" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Remission (DoR1) for Participants Who Achieved CR or CRi</title>
        <description>DoR1 was defined for participants who responded as the time from the date of first documentation of Complete Hematologic Response (CR or CRi) to the date of the first documentation of relapse after CR or CRi, treatment discontinuation due to global deterioration of health status) or to death due to any cause. Participants last known to be 1) alive and 2) without a DoR1 event, were censored at the date of the last disease assessment that verified lack of event.</description>
        <time_frame>Up to approximately 2 years from first dose</time_frame>
        <population>All participants who achieved CR or CRi</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Duration of Remission (DoR1) for Participants Who Achieved CR or CRi</title>
          <description>DoR1 was defined for participants who responded as the time from the date of first documentation of Complete Hematologic Response (CR or CRi) to the date of the first documentation of relapse after CR or CRi, treatment discontinuation due to global deterioration of health status) or to death due to any cause. Participants last known to be 1) alive and 2) without a DoR1 event, were censored at the date of the last disease assessment that verified lack of event.</description>
          <population>All participants who achieved CR or CRi</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="4.6" upper_limit="4.8"/>
                    <measurement group_id="O2" value="NA" lower_limit="0.7">Median and upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O3" value="10.8" lower_limit="1.2">Upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O4" value="7.1" lower_limit="2.1">Upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O5" value="3.8" lower_limit="2.2" upper_limit="5.8"/>
                    <measurement group_id="O6" value="4.8" lower_limit="3.8" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR) for Participants Who Achieved CR/CRi or PR</title>
        <description>DoR was defined for participants who respond as the time from the date of first documentation of Hematologic Response (CR, CRi, or PR) to the date of the first documentation of DoR event (earliest date of PD, treatment discontinuation due to global deterioration of health status, first induction therapy or transplant after PR, relapse after CR or CRi or death due to any cause). Participants last known to be 1) alive and 2) without a DoR event, were censored at the date of the last disease assessment that verified lack of event.</description>
        <time_frame>Up to approximately 2 years from first dose</time_frame>
        <population>All participants who achieved CR, CRi or PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR) for Participants Who Achieved CR/CRi or PR</title>
          <description>DoR was defined for participants who respond as the time from the date of first documentation of Hematologic Response (CR, CRi, or PR) to the date of the first documentation of DoR event (earliest date of PD, treatment discontinuation due to global deterioration of health status, first induction therapy or transplant after PR, relapse after CR or CRi or death due to any cause). Participants last known to be 1) alive and 2) without a DoR event, were censored at the date of the last disease assessment that verified lack of event.</description>
          <population>All participants who achieved CR, CRi or PR.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.50" lower_limit="20.1" upper_limit="20.9"/>
                    <measurement group_id="O2" value="NA" lower_limit="3.1">Median and upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O3" value="46.93" lower_limit="7.6">Upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O4" value="31.07" lower_limit="12.1">Upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O5" value="16.57" lower_limit="9.9" upper_limit="24.0"/>
                    <measurement group_id="O6" value="18.71" lower_limit="12.6" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from Cycle 1 Day 1 to date of death due to any cause. If death was not documented, censoring occurred at the date at which the participant was last known to be alive.</description>
        <time_frame>Up to approximately 2 years from first dose</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from Cycle 1 Day 1 to date of death due to any cause. If death was not documented, censoring occurred at the date at which the participant was last known to be alive.</description>
          <population>Safety analysis set</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="2.1" upper_limit="11.3"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.6">Median and upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O3" value="16.5" lower_limit="2.6">Upper 95% CI may not have been reached at the time of data analysis.</measurement>
                    <measurement group_id="O4" value="5.8" lower_limit="3.5" upper_limit="10.8"/>
                    <measurement group_id="O5" value="6.4" lower_limit="4.5" upper_limit="7.9"/>
                    <measurement group_id="O6" value="7.4" lower_limit="5.7" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Remission for Participants Who Achieved CR or CRi</title>
        <description>Time to remission was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic remission (CR or CRi) in participants achieving remission during study therapy.</description>
        <time_frame>Up to approximately 2 years from first dose</time_frame>
        <population>All participants who achieved CR or CRi</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Remission for Participants Who Achieved CR or CRi</title>
          <description>Time to remission was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic remission (CR or CRi) in participants achieving remission during study therapy.</description>
          <population>All participants who achieved CR or CRi</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="24.04" lower_limit="22" upper_limit="56"/>
                    <measurement group_id="O2" value="29.0" spread="12.60" lower_limit="22" upper_limit="59"/>
                    <measurement group_id="O3" value="38.0" spread="19.88" lower_limit="22" upper_limit="78"/>
                    <measurement group_id="O4" value="27.0" spread="29.18" lower_limit="21" upper_limit="85"/>
                    <measurement group_id="O5" value="25.5" spread="22.12" lower_limit="15" upper_limit="91"/>
                    <measurement group_id="O6" value="27.0" spread="20.75" lower_limit="15" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response for Participants Who Achieved CR/CRi or PR</title>
        <description>Time to response was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic response (CR, CRi, or PR).</description>
        <time_frame>Up to approximately 2 years from first dose</time_frame>
        <population>All participants who achieved CR, CRi or PR.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Response for Participants Who Achieved CR/CRi or PR</title>
          <description>Time to response was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic response (CR, CRi, or PR).</description>
          <population>All participants who achieved CR, CRi or PR.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="24.04" lower_limit="22" upper_limit="56"/>
                    <measurement group_id="O2" value="29.0" spread="9.01" lower_limit="22" upper_limit="49"/>
                    <measurement group_id="O3" value="27.0" spread="20.66" lower_limit="20" upper_limit="78"/>
                    <measurement group_id="O4" value="24.0" spread="10.09" lower_limit="21" upper_limit="48"/>
                    <measurement group_id="O5" value="23.0" spread="10.22" lower_limit="15" upper_limit="58"/>
                    <measurement group_id="O6" value="25.0" spread="12.45" lower_limit="15" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to MRD Negativity for Participants Who Achieved CR or CRi</title>
        <description>Time to MRD negativity was defined as the time from the date of first dose of study drug to the date of first documentation of MRD negativity.</description>
        <time_frame>Screening, Day 21 of Cycles 1 to 6 and up to 4 to 6 weeks after the last dose (up to 34 weeks)</time_frame>
        <population>All participants who achieved CR/CRi and MRD negativity.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Time to MRD Negativity for Participants Who Achieved CR or CRi</title>
          <description>Time to MRD negativity was defined as the time from the date of first dose of study drug to the date of first documentation of MRD negativity.</description>
          <population>All participants who achieved CR/CRi and MRD negativity.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" spread="0.71" lower_limit="98" upper_limit="99"/>
                    <measurement group_id="O2" value="32.0" spread="15.17" lower_limit="22" upper_limit="64"/>
                    <measurement group_id="O3" value="30.0" spread="50.54" lower_limit="22" upper_limit="141"/>
                    <measurement group_id="O4" value="25.0" spread="48.09" lower_limit="21" upper_limit="134"/>
                    <measurement group_id="O5" value="25.5" spread="18.66" lower_limit="21" upper_limit="80"/>
                    <measurement group_id="O6" value="29.0" spread="32.73" lower_limit="21" upper_limit="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Follow-Up</title>
        <description>Duration of follow-up was defined as the time from the date of first dose of study drug to the date of last contact for participants known to be alive.</description>
        <time_frame>From first dose up to approximately 2 years</time_frame>
        <population>Participants who were alive</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Duration of Follow-Up</title>
          <description>Duration of follow-up was defined as the time from the date of first dose of study drug to the date of last contact for participants known to be alive.</description>
          <population>Participants who were alive</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="24.0" lower_limit="22.9" upper_limit="29.7"/>
                    <measurement group_id="O3" value="25.7" lower_limit="24.1" upper_limit="26.5"/>
                    <measurement group_id="O4" value="24.1" lower_limit="23.9" upper_limit="26.9"/>
                    <measurement group_id="O5" value="24.2" lower_limit="6.8" upper_limit="24.5"/>
                    <measurement group_id="O6" value="24.1" lower_limit="24.0" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Cluster of Differentiation-22 Positive (CD22+) Leukemic Blasts in Abnormal B Cells in Blood by Visit</title>
        <description>CD22+ leukemic blasts assessed in abnormal B cells from blood (data from central laboratories only).</description>
        <time_frame>Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Cluster of Differentiation-22 Positive (CD22+) Leukemic Blasts in Abnormal B Cells in Blood by Visit</title>
          <description>CD22+ leukemic blasts assessed in abnormal B cells from blood (data from central laboratories only).</description>
          <population>Safety analysis set</population>
          <units>Percentage of CD22+</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O2" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O3" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O4" value="93.7" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O5" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O6" value="93.7" lower_limit="88" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="57" upper_limit="100"/>
                    <measurement group_id="O2" value="98.1" lower_limit="67" upper_limit="100"/>
                    <measurement group_id="O3" value="98.4" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O4" value="96.4" lower_limit="65" upper_limit="100"/>
                    <measurement group_id="O5" value="98.7" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O6" value="98.0" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" lower_limit="31" upper_limit="99"/>
                    <measurement group_id="O2" value="79.0" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="99"/>
                    <measurement group_id="O4" value="71.4" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O5" value="74.8" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O6" value="69.9" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" lower_limit="6" upper_limit="100"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="92"/>
                    <measurement group_id="O4" value="2.8" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="98"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0" upper_limit="99"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="73"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="38"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="99" upper_limit="99"/>
                    <measurement group_id="O2" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O3" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O4" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O5" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O6" value="99.0" lower_limit="99" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of CD22+ Leukemic Blasts in Abnormal B Cells in Bone Marrow by Visit</title>
        <description>CD22+ leukemic blasts assessed in abnormal B cells from bone marrow (data from central laboratories only).</description>
        <time_frame>Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 - Dose Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O4">
            <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O5">
            <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
            <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
          </group>
          <group group_id="O6">
            <title>All Doses</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of CD22+ Leukemic Blasts in Abnormal B Cells in Bone Marrow by Visit</title>
          <description>CD22+ leukemic blasts assessed in abnormal B cells from bone marrow (data from central laboratories only).</description>
          <population>Safety analysis set</population>
          <units>Percentage of CD22+</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="98.7" lower_limit="31" upper_limit="100"/>
                    <measurement group_id="O3" value="98.4" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O4" value="95.1" lower_limit="52" upper_limit="100"/>
                    <measurement group_id="O5" value="99.2" lower_limit="78" upper_limit="100"/>
                    <measurement group_id="O6" value="99.0" lower_limit="31" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O2" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O3" value="99" lower_limit="99" upper_limit="99"/>
                    <measurement group_id="O4" value="56.5" lower_limit="39" upper_limit="74"/>
                    <measurement group_id="O5" value="70.7" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O6" value="72.3" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="52" upper_limit="99"/>
                    <measurement group_id="O2" value="54.1" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O3" value="26.5" lower_limit="0" upper_limit="99"/>
                    <measurement group_id="O4" value="74.1" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O5" value="94.5" lower_limit="20" upper_limit="100"/>
                    <measurement group_id="O6" value="56.6" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O4" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="96"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="6" upper_limit="100"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="31"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="72"/>
                    <measurement group_id="O4" value="2.9" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O5" value="6.8" lower_limit="0" upper_limit="78"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O2" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="71"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="13"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="78"/>
                    <measurement group_id="O5" value="25.1" lower_limit="0" upper_limit="50"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="97" upper_limit="97"/>
                    <measurement group_id="O2" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O3" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O4" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O5" value="11.6" lower_limit="0" upper_limit="45"/>
                    <measurement group_id="O6" value="23.2" lower_limit="0" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="14.3" lower_limit="2" upper_limit="27"/>
                    <measurement group_id="O4" value="29.4" lower_limit="0" upper_limit="59"/>
                    <measurement group_id="O5" value="36" lower_limit="36" upper_limit="36"/>
                    <measurement group_id="O6" value="1.9" lower_limit="0" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O2" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O3" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="66.4" lower_limit="48" upper_limit="85"/>
                    <measurement group_id="O6" value="48.1" lower_limit="0" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O3" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O4" value="79.1" lower_limit="0" upper_limit="99"/>
                    <measurement group_id="O5" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O6" value="39.6" lower_limit="0" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O2" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O3" value="NA">Median and CI not determined since n = 0</measurement>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="74" lower_limit="74" upper_limit="74"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="6.6" lower_limit="2" upper_limit="11"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="94"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Messenger Ribonucleic Acid (mRNA) Gene Expression</title>
        <description>Optional blood samples for pharmacogenomic parameters were collected during Cycle 1 prior to the start of the inotuzumab ozogamicin infusion (0 hours) and 1 hour post-dose (original Final Protocol and Protocol Amendments 1 and 2) or 3 hours post-dose (Protocol Amendments 3 and 4) on Day 1 and Day 15 from those participants who provided consent. Gene expression analysis of samples collected pre- and post-dosing was performed using 96-gene TaqMan® low density array cards to examine the concordance between clinical outcome and expression of genes such as those involved in DNA damage response, apoptosis, B-cell antigen expression, glutathione metabolism, drug transport and the phosphoinositide 3-kinase/mammalian target of rapamycin pathway. Expression for each gene was reported as a normalized value, 2^–change in (∆) threshold cycle (Ct), where ∆Ct is Ct^target gene minus Ct^reference genes, averaged.</description>
        <time_frame>Predose and postdose on Days 1 and 15 of Cycle 1</time_frame>
        <population>Pharmacogenomics population - included all enrolled participants who received at least 1 dose of any study drug, and had at least 1 biomarker parameter from the corresponding assay sample with both a baseline and post-treatment assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pharmacogenomics Population</title>
            <description>All participants who gave consent for the optional blood sample for pharmacogenomic analyses, received at least 1 dose of any study drug, and had at least 1 biomarker parameter from the corresponding assay sample with both a baseline and post-treatment assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Messenger Ribonucleic Acid (mRNA) Gene Expression</title>
          <description>Optional blood samples for pharmacogenomic parameters were collected during Cycle 1 prior to the start of the inotuzumab ozogamicin infusion (0 hours) and 1 hour post-dose (original Final Protocol and Protocol Amendments 1 and 2) or 3 hours post-dose (Protocol Amendments 3 and 4) on Day 1 and Day 15 from those participants who provided consent. Gene expression analysis of samples collected pre- and post-dosing was performed using 96-gene TaqMan® low density array cards to examine the concordance between clinical outcome and expression of genes such as those involved in DNA damage response, apoptosis, B-cell antigen expression, glutathione metabolism, drug transport and the phosphoinositide 3-kinase/mammalian target of rapamycin pathway. Expression for each gene was reported as a normalized value, 2^–change in (∆) threshold cycle (Ct), where ∆Ct is Ct^target gene minus Ct^reference genes, averaged.</description>
          <population>Pharmacogenomics population - included all enrolled participants who received at least 1 dose of any study drug, and had at least 1 biomarker parameter from the corresponding assay sample with both a baseline and post-treatment assessment.</population>
          <units>Fold expression</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ABCB1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00421" lower_limit="0.0002" upper_limit="0.0217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCB1: Cycle 1 Day 1, Post-dose (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00440" lower_limit="0.0003" upper_limit="0.0313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCB1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00746" lower_limit="0.0004" upper_limit="0.0218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCB1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00783" lower_limit="0.0005" upper_limit="0.0364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCC1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01983" lower_limit="0.0041" upper_limit="0.0885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCC1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02245" lower_limit="0.0044" upper_limit="0.0737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCC1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01453" lower_limit="0.0062" upper_limit="0.0413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCC1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01497" lower_limit="0.0042" upper_limit="0.0578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCC2: Cycle 1 Day 1, Baseline (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00064" lower_limit="0.0002" upper_limit="0.0020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCC2: Cycle 1 Day 1, Post-dose (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00072" lower_limit="0.0002" upper_limit="0.0020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCC2: Cycle 1 Day 15, 0 hours (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00072" lower_limit="0.0002" upper_limit="0.0015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCC2: Cycle 1 Day 15, Post-dose (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00078" lower_limit="0.0003" upper_limit="0.0023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCG2: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00491" lower_limit="0.0003" upper_limit="0.0509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCG2: Cycle 1 Day 1, Post-dose (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00660" lower_limit="0.0002" upper_limit="0.0431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCG2: Cycle 1 Day 15, 0 hours (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01582" lower_limit="0.0014" upper_limit="0.0818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCG2: Cycle 1 Day 15, Post-dose (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01845" lower_limit="0.0010" upper_limit="0.0921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03297" lower_limit="0.0027" upper_limit="0.1982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02899" lower_limit="0.0032" upper_limit="0.1382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01369" lower_limit="0.0043" upper_limit="0.0632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01381" lower_limit="0.0032" upper_limit="0.0783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL2: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00916" lower_limit="0.0029" upper_limit="0.0329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL2: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00867" lower_limit="0.0021" upper_limit="0.0268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL2: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00613" lower_limit="0.0032" upper_limit="0.0184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABL2: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00547" lower_limit="0.0029" upper_limit="0.0224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTB: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73899" lower_limit="0.5853" upper_limit="4.0764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTB: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95092" lower_limit="0.7314" upper_limit="3.3585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTB: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14694" lower_limit="1.3915" upper_limit="5.3955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACTB: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11584" lower_limit="1.3279" upper_limit="7.3316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AKT1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03212" lower_limit="0.0112" upper_limit="0.0793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AKT1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03164" lower_limit="0.0116" upper_limit="0.0738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AKT1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02740" lower_limit="0.0108" upper_limit="0.0572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AKT1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02987" lower_limit="0.0078" upper_limit="0.0672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALG5: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00455" lower_limit="0.0004" upper_limit="0.0206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALG5: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00419" lower_limit="0.0007" upper_limit="0.0173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALG5: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00302" lower_limit="0.0013" upper_limit="0.0064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALG5: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00265" lower_limit="0.0006" upper_limit="0.0060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APAF1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03880" lower_limit="0.0074" upper_limit="0.0896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APAF1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03740" lower_limit="0.0072" upper_limit="0.1051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APAF1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03754" lower_limit="0.0138" upper_limit="0.0763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APAF1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03708" lower_limit="0.0128" upper_limit="0.0918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATM: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06441" lower_limit="0.0121" upper_limit="0.1845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATM: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06615" lower_limit="0.0125" upper_limit="0.1497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATM: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06927" lower_limit="0.0297" upper_limit="0.1439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATM: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05951" lower_limit="0.0262" upper_limit="0.1247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATRX: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06123" lower_limit="0.0177" upper_limit="0.2406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATRX: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05679" lower_limit="0.0194" upper_limit="0.2183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATRX: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05456" lower_limit="0.0179" upper_limit="0.1074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATRX: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05662" lower_limit="0.0211" upper_limit="0.1142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2M: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.81650" lower_limit="1.2559" upper_limit="9.9074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2M: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89919" lower_limit="1.2108" upper_limit="11.9448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2M: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.97465" lower_limit="1.1943" upper_limit="10.8448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2M: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21338" lower_limit="1.5174" upper_limit="12.9707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAD: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00099" lower_limit="0.0004" upper_limit="0.0053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAD: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00100" lower_limit="0.0003" upper_limit="0.0067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAD: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00085" lower_limit="0.0003" upper_limit="0.0021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAD: Cycle 1 Day 15, Post-dose (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00077" lower_limit="0.0004" upper_limit="0.0026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAK1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01991" lower_limit="0.0031" upper_limit="0.2253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAK1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01658" lower_limit="0.0024" upper_limit="0.1570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAK1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01490" lower_limit="0.0050" upper_limit="0.0313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAK1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01405" lower_limit="0.0045" upper_limit="0.0302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAX: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07686" lower_limit="0.0290" upper_limit="0.1825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAX: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07420" lower_limit="0.0284" upper_limit="0.1904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAX: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07107" lower_limit="0.0346" upper_limit="0.1387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAX: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06543" lower_limit="0.0304" upper_limit="0.1316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BBC3: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01174" lower_limit="0.0031" upper_limit="0.0445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BBC3: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01197" lower_limit="0.0044" upper_limit="0.0384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BBC3: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01470" lower_limit="0.0052" upper_limit="0.0335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BBC3: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01449" lower_limit="0.0061" upper_limit="0.0390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02425" lower_limit="0.0021" upper_limit="0.0958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02200" lower_limit="0.0024" upper_limit="0.1014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01979" lower_limit="0.0037" upper_limit="0.0703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01648" lower_limit="0.0042" upper_limit="0.0851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2L1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83473" lower_limit="0.0227" upper_limit="11.2775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2L1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12931" lower_limit="0.0200" upper_limit="14.5203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2L1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05721" lower_limit="0.0236" upper_limit="15.0024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2L1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98955" lower_limit="0.0220" upper_limit="18.3879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2L11: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03003" lower_limit="0.0025" upper_limit="0.1197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2L11: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02970" lower_limit="0.0029" upper_limit="0.0916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2L11: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03865" lower_limit="0.0151" upper_limit="0.0817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCL2L11: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04259" lower_limit="0.0164" upper_limit="0.0825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCR: Cycle 1 Day 1, Baseline (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02294" lower_limit="0.0006" upper_limit="0.0858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCR: Cycle 1 Day 1, Post-dose (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02135" lower_limit="0.0008" upper_limit="0.0967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCR: Cycle 1 Day 15, 0 hours (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00116" lower_limit="0.0003" upper_limit="0.0108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BCR: Cycle 1 Day 15, Post-dose (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00817" lower_limit="0.0013" upper_limit="0.0150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BID: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01794" lower_limit="0.0076" upper_limit="0.0458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BID: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01528" lower_limit="0.0060" upper_limit="0.0436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BID: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01619" lower_limit="0.0071" upper_limit="0.0313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BID: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01448" lower_limit="0.0043" upper_limit="0.0518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIK: Cycle 1 Day 1, Baseline (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00137" lower_limit="0.0001" upper_limit="0.0220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIK: Cycle 1 Day 1, Post-dose (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00143" lower_limit="0.0001" upper_limit="0.0228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIK: Cycle 1 Day 15, 0 hours (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00093" lower_limit="0.0005" upper_limit="0.0038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIK: Cycle 1 Day 15, Post-dose (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00095" lower_limit="0.0004" upper_limit="0.0049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMF: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00604" lower_limit="0.0011" upper_limit="0.0579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMF: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00705" lower_limit="0.0009" upper_limit="0.0807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMF: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00333" lower_limit="0.0010" upper_limit="0.0156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMF: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00341" lower_limit="0.0006" upper_limit="0.0429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00628" lower_limit="0.0017" upper_limit="0.0395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00691" lower_limit="0.0019" upper_limit="0.0367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00385" lower_limit="0.0019" upper_limit="0.0133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00416" lower_limit="0.0024" upper_limit="0.0175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA2: Cycle 1 Day 1, Baseline (n=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00059" lower_limit="0.0002" upper_limit="0.0023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA2: Cycle 1 Day 1, Post-dose (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00067" lower_limit="0.0002" upper_limit="0.0020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA2: Cycle 1 Day 15, 0 hours (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00045" lower_limit="0.0003" upper_limit="0.0015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA2: Cycle 1 Day 15, Post-dose (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00049" lower_limit="0.0003" upper_limit="0.0012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA6: Cycle 1 Day 1, Baseline (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00104" lower_limit="0.0001" upper_limit="0.1076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA6: Cycle 1 Day 1, Post-dose (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00196" lower_limit="0.0000" upper_limit="0.1364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA6: Cycle 1 Day 15, 0 hours (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00130" lower_limit="0.0002" upper_limit="0.0425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CA6: Cycle 1 Day 15, Post-dose (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00119" lower_limit="0.0003" upper_limit="0.0576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP2: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04235" lower_limit="0.0161" upper_limit="0.1661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP2: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04162" lower_limit="0.0141" upper_limit="0.1175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP2: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03287" lower_limit="0.0201" upper_limit="0.1092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP2: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03283" lower_limit="0.0190" upper_limit="0.1097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP3: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02380" lower_limit="0.0091" upper_limit="0.0608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP3: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02353" lower_limit="0.0046" upper_limit="0.0741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP3: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02168" lower_limit="0.0102" upper_limit="0.0404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP3: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02030" lower_limit="0.0068" upper_limit="0.0429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP7: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01271" lower_limit="0.0032" upper_limit="0.0364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP7: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01354" lower_limit="0.0024" upper_limit="0.0278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP7: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00923" lower_limit="0.0026" upper_limit="0.0235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP7: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00833" lower_limit="0.0016" upper_limit="0.0196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP9: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00772" lower_limit="0.0039" upper_limit="0.0211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP9: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00732" lower_limit="0.0033" upper_limit="0.0218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP9: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00707" lower_limit="0.0042" upper_limit="0.0120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CASP9: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00715" lower_limit="0.0037" upper_limit="0.0135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCND1: Cycle 1 Day 1, Baseline (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00091" lower_limit="0.0001" upper_limit="0.0309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCND1: Cycle 1 Day 1, Post-dose (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00071" lower_limit="0.0001" upper_limit="0.0153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCND1: Cycle 1 Day 15, 0 hours (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00080" lower_limit="0.0002" upper_limit="0.0067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCND1: Cycle 1 Day 15, Post-dose (n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00078" lower_limit="0.0002" upper_limit="0.0044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCNE1: Cycle 1 Day 1, Baseline (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00311" lower_limit="0.0003" upper_limit="0.0371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCNE1: Cycle 1 Day 1, Post-dose (n=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00331" lower_limit="0.0005" upper_limit="0.0318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCNE1: Cycle 1 Day 15, 0 hours (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00234" lower_limit="0.0004" upper_limit="0.0136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCNE1: Cycle 1 Day 15, Post-dose (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00217" lower_limit="0.0002" upper_limit="0.0080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD22: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04313" lower_limit="0.0005" upper_limit="0.7239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD22: Cycle 1 Day 1, Post-dose (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03359" lower_limit="0.0007" upper_limit="0.6010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD22: Cycle 1 Day 15, 0 hours (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00120" lower_limit="0.0002" upper_limit="0.0559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD22: Cycle 1 Day 15, Post-dose (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00130" lower_limit="0.0002" upper_limit="0.0684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD24: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31881" lower_limit="0.0232" upper_limit="2.6309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD24: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36597" lower_limit="0.0237" upper_limit="3.0720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD24: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02968" lower_limit="0.0019" upper_limit="0.5446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD24: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05363" lower_limit="0.0036" upper_limit="0.6901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD44: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25285" lower_limit="0.1254" upper_limit="0.8904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD44: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23497" lower_limit="0.0996" upper_limit="0.7828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD44: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27359" lower_limit="0.1607" upper_limit="0.6984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD44: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22892" lower_limit="0.1309" upper_limit="0.6394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD70: Cycle 1 Day 1, Baseline (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00194" lower_limit="0.0000" upper_limit="0.0282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD70: Cycle 1 Day 1, Post-dose (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00170" lower_limit="0.0001" upper_limit="0.0291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD70: Cycle 1 Day 15, 0 hours (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00225" lower_limit="0.0002" upper_limit="0.0115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD70: Cycle 1 Day 15, Post-dose (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00169" lower_limit="0.0001" upper_limit="0.0135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC25A: Cycle 1 Day 1, Baseline (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00337" lower_limit="0.0003" upper_limit="0.0290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC25A: Cycle 1 Day 1, Post-dose (n=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00334" lower_limit="0.0003" upper_limit="0.0292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC25A: Cycle 1 Day 15, 0 hours (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00115" lower_limit="0.0002" upper_limit="0.0100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDC25A: Cycle 1 Day 15, Post-dose (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00116" lower_limit="0.0002" upper_limit="0.0098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDK2: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02026" lower_limit="0.0028" upper_limit="0.0786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDK2: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01883" lower_limit="0.0031" upper_limit="0.0786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDK2: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01109" lower_limit="0.0043" upper_limit="0.0389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDK2: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01118" lower_limit="0.0039" upper_limit="0.0458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDKN2A: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00675" lower_limit="0.0002" upper_limit="0.7546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDKN2A: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00667" lower_limit="0.0002" upper_limit="0.7308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDKN2A: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00676" lower_limit="0.0001" upper_limit="0.0892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDKN2A: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00661" lower_limit="0.0001" upper_limit="0.1001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHEK2: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00257" lower_limit="0.0008" upper_limit="0.0067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHEK2: Cycle 1 Day 1, Post-dose (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00224" lower_limit="0.0008" upper_limit="0.0069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHEK2: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00206" lower_limit="0.0006" upper_limit="0.0077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHEK2: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00234" lower_limit="0.0009" upper_limit="0.0093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAPK1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02015" lower_limit="0.0005" upper_limit="0.2850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAPK1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02089" lower_limit="0.0002" upper_limit="0.2330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAPK1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01627" lower_limit="0.0017" upper_limit="0.0447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAPK1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01769" lower_limit="0.0018" upper_limit="0.0544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DCLRE1C: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01404" lower_limit="0.0030" upper_limit="0.0550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DCLRE1C: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01226" lower_limit="0.0028" upper_limit="0.0539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DCLRE1C: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00845" lower_limit="0.0034" upper_limit="0.0162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DCLRE1C: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00875" lower_limit="0.0031" upper_limit="0.0243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DDIT4L: Cycle 1 Day 1, Baseline (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00091" lower_limit="0.0001" upper_limit="0.0322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DDIT4L: Cycle 1 Day 1, Post-dose (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00081" lower_limit="0.0001" upper_limit="0.0169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DDIT4L: Cycle 1 Day 15, 0 hours (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00058" lower_limit="0.0002" upper_limit="0.0093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DDIT4L: Cycle 1 Day 15, Post-dose (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00052" lower_limit="0.0002" upper_limit="0.0115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EBF1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02830" lower_limit="0.0005" upper_limit="0.3909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EBF1: Cycle 1 Day 1, Post-dose (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02492" lower_limit="0.0006" upper_limit="0.3346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EBF1: Cycle 1 Day 15, 0 hours (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00112" lower_limit="0.0001" upper_limit="0.0761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EBF1: Cycle 1 Day 15, Post-dose (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00112" lower_limit="0.0002" upper_limit="0.1217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EEF1D: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00250" lower_limit="0.0006" upper_limit="0.0115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EEF1D: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00246" lower_limit="0.0008" upper_limit="0.0108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EEF1D: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00181" lower_limit="0.0007" upper_limit="0.0051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EEF1D: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00186" lower_limit="0.0010" upper_limit="0.0059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FADD: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00436" lower_limit="0.0022" upper_limit="0.0192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FADD: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00487" lower_limit="0.0018" upper_limit="0.0309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FADD: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00434" lower_limit="0.0022" upper_limit="0.0117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FADD: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00477" lower_limit="0.0024" upper_limit="0.0127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02458" lower_limit="0.0041" upper_limit="0.0651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02634" lower_limit="0.0042" upper_limit="0.0846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03444" lower_limit="0.0107" upper_limit="0.0735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03547" lower_limit="0.0124" upper_limit="0.0882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FASLG: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00312" lower_limit="0.0003" upper_limit="0.0281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FASLG: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00343" lower_limit="0.0004" upper_limit="0.0248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FASLG: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00873" lower_limit="0.0004" upper_limit="0.0338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FASLG: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00820" lower_limit="0.0005" upper_limit="0.0259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GAPDH: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77798" lower_limit="0.3626" upper_limit="2.3473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GAPDH: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74570" lower_limit="0.3086" upper_limit="1.9921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GAPDH: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46996" lower_limit="0.3306" upper_limit="1.4609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GAPDH: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43709" lower_limit="0.2622" upper_limit="1.3683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLI3: Cycle 1 Day 1, Baseline (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00098" lower_limit="0.0001" upper_limit="0.0101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLI3: Cycle 1 Day 1, Post-dose (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00107" lower_limit="0.0001" upper_limit="0.0097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLI3: Cycle 1 Day 15, 0 hours (n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00041" lower_limit="0.0002" upper_limit="0.0051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLI3: Cycle 1 Day 15, Post-dose (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00054" lower_limit="0.0004" upper_limit="0.0070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTA2: Cycle 1 Day 1, Baseline (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00218" lower_limit="0.0001" upper_limit="0.1397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTA2: Cycle 1 Day 1, Post-dose (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00033" lower_limit="0.0002" upper_limit="0.0086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTA2: Cycle 1 Day 15, Post-dose (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00069" lower_limit="0.0006" upper_limit="0.0008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM1: Cycle 1 Day 1, Baseline (n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00958" lower_limit="0.0007" upper_limit="0.0394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM1: Cycle 1 Day 1, Post-dose (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00885" lower_limit="0.0009" upper_limit="0.0334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM1: Cycle 1 Day 15, 0 hours (n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00706" lower_limit="0.0004" upper_limit="0.0370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM1: Cycle 1 Day 15, Post-dose (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00642" lower_limit="0.0004" upper_limit="0.0351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM4: Cycle 1 Day 1, Baseline (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00260" lower_limit="0.0003" upper_limit="0.0132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM4: Cycle 1 Day 1, Post-dose (n=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00237" lower_limit="0.0004" upper_limit="0.0134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM4: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00226" lower_limit="0.0005" upper_limit="0.0091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM4: Cycle 1 Day 15, Post-dose (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00225" lower_limit="0.0003" upper_limit="0.0098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM5: Cycle 1 Day 1, Baseline (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00045" lower_limit="0.0000" upper_limit="0.0078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM5: Cycle 1 Day 1, Post-dose (n=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00050" lower_limit="0.0000" upper_limit="0.0074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM5: Cycle 1 Day 15, 0 hours (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00065" lower_limit="0.0001" upper_limit="0.0049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTM5: Cycle 1 Day 15, Post-dose (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00094" lower_limit="0.0002" upper_limit="0.0051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTP1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28876" lower_limit="0.0344" upper_limit="1.6475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTP1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28295" lower_limit="0.0378" upper_limit="1.2982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTP1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19381" lower_limit="0.0349" upper_limit="0.9610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTP1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19224" lower_limit="0.0276" upper_limit="0.9227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTT1: Cycle 1 Day 1, Baseline (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00061" lower_limit="0.0000" upper_limit="0.0030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTT1: Cycle 1 Day 1, Post-dose (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00065" lower_limit="0.0001" upper_limit="0.0027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTT1: Cycle 1 Day 15, 0 hours (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00064" lower_limit="0.0002" upper_limit="0.0033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSTT1: Cycle 1 Day 15, Post-dose (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00066" lower_limit="0.0002" upper_limit="0.0031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRK: Cycle 1 Day 1, Baseline (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00136" lower_limit="0.0001" upper_limit="0.0635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRK: Cycle 1 Day 1, Post-dose (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00108" lower_limit="0.0001" upper_limit="0.0526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRK: Cycle 1 Day 15, 0 hours (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00075" lower_limit="0.0002" upper_limit="0.0041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HRK: Cycle 1 Day 15, Post-dose (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00055" lower_limit="0.0001" upper_limit="0.0060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IKZF1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22553" lower_limit="0.0053" upper_limit="0.6277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IKZF1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25975" lower_limit="0.0204" upper_limit="0.5414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IKZF1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23670" lower_limit="0.0072" upper_limit="0.5148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IKZF1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23925" lower_limit="0.0072" upper_limit="0.5646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KMT2A: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03764" lower_limit="0.0040" upper_limit="0.1704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KMT2A: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03459" lower_limit="0.0042" upper_limit="0.1663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KMT2A: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02499" lower_limit="0.0090" upper_limit="0.0708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KMT2A: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02138" lower_limit="0.0066" upper_limit="0.0844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KRT20: Cycle 1 Day 1, Baseline (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00018" lower_limit="0.0001" upper_limit="0.0002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LEF1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18940" lower_limit="0.0077" upper_limit="1.7280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LEF1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14479" lower_limit="0.0089" upper_limit="1.6906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LEF1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07819" lower_limit="0.0150" upper_limit="0.5602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LEF1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05586" lower_limit="0.0121" upper_limit="0.8065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCL1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42021" lower_limit="0.1390" upper_limit="1.0057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCL1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44770" lower_limit="0.1628" upper_limit="1.2938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCL1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52160" lower_limit="0.2694" upper_limit="1.4203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCL1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61933" lower_limit="0.2389" upper_limit="2.6947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01825" lower_limit="0.0012" upper_limit="0.0535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01825" lower_limit="0.0012" upper_limit="0.0418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01109" lower_limit="0.0027" upper_limit="0.0346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MDC1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01034" lower_limit="0.0022" upper_limit="0.0411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRE11A: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00708" lower_limit="0.0010" upper_limit="0.0210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRE11A: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00672" lower_limit="0.0010" upper_limit="0.0277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRE11A: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00484" lower_limit="0.0017" upper_limit="0.0109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRE11A: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00508" lower_limit="0.0017" upper_limit="0.0147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MTOR: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01585" lower_limit="0.0027" upper_limit="0.0498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MTOR: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01636" lower_limit="0.0029" upper_limit="0.0521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MTOR: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01088" lower_limit="0.0048" upper_limit="0.0288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MTOR: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01122" lower_limit="0.0041" upper_limit="0.0513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NHEJ1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01162" lower_limit="0.0026" upper_limit="0.0353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NHEJ1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01164" lower_limit="0.0030" upper_limit="0.0352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NHEJ1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00974" lower_limit="0.0040" upper_limit="0.0233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NHEJ1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01008" lower_limit="0.0034" upper_limit="0.0271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NLRP2: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00237" lower_limit="0.0002" upper_limit="0.0181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NLRP2: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00226" lower_limit="0.0004" upper_limit="0.0168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NLRP2: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00301" lower_limit="0.0002" upper_limit="0.0091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NLRP2: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00283" lower_limit="0.0002" upper_limit="0.0084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOXA1: Cycle 1 Day 1, Baseline (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00097" lower_limit="0.0001" upper_limit="0.0079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOXA1: Cycle 1 Day 1, Post-dose (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00107" lower_limit="0.0001" upper_limit="0.0069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOXA1: Cycle 1 Day 15, 0 hours (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00132" lower_limit="0.0003" upper_limit="0.0032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOXA1: Cycle 1 Day 15, Post-dose (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00117" lower_limit="0.0003" upper_limit="0.0032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAX5: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05536" lower_limit="0.0004" upper_limit="1.1631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAX5: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04433" lower_limit="0.0007" upper_limit="0.8454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAX5: Cycle 1 Day 15, 0 hours (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00511" lower_limit="0.0002" upper_limit="0.1024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAX5: Cycle 1 Day 15, Post-dose (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00369" lower_limit="0.0001" upper_limit="0.2123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDE4A: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00738" lower_limit="0.0012" upper_limit="0.0578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDE4A: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00722" lower_limit="0.0007" upper_limit="0.0566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDE4A: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00916" lower_limit="0.0019" upper_limit="0.0202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDE4A: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00836" lower_limit="0.0025" upper_limit="0.0235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGK1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19043" lower_limit="0.1270" upper_limit="0.5490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGK1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18772" lower_limit="0.1103" upper_limit="0.5287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGK1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14989" lower_limit="0.0898" upper_limit="0.2804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGK1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14783" lower_limit="0.0649" upper_limit="0.2701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIK3CA: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01664" lower_limit="0.0057" upper_limit="0.0496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIK3CA: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01714" lower_limit="0.0066" upper_limit="0.0535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIK3CA: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01154" lower_limit="0.0068" upper_limit="0.0290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIK3CA: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01164" lower_limit="0.0053" upper_limit="0.0273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRKDC: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03206" lower_limit="0.0023" upper_limit="0.1691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRKDC: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03543" lower_limit="0.0023" upper_limit="0.1525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRKDC: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01964" lower_limit="0.0049" upper_limit="0.0638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRKDC: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02159" lower_limit="0.0051" upper_limit="0.0826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD50: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01482" lower_limit="0.0017" upper_limit="0.0593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD50: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01516" lower_limit="0.0019" upper_limit="0.0525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD50: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01129" lower_limit="0.0041" upper_limit="0.0238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD50: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01044" lower_limit="0.0026" upper_limit="0.0244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD51: Cycle 1 Day 1, Baseline (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00558" lower_limit="0.0015" upper_limit="0.0484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD51: Cycle 1 Day 1, Post-dose (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00573" lower_limit="0.0010" upper_limit="0.0502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD51: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00382" lower_limit="0.0009" upper_limit="0.0222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD51: Cycle 1 Day 15, Post-dose (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00356" lower_limit="0.0004" upper_limit="0.0225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD52: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00384" lower_limit="0.0007" upper_limit="0.0129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD52: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00330" lower_limit="0.0006" upper_limit="0.0115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD52: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00221" lower_limit="0.0008" upper_limit="0.0184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RAD52: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00211" lower_limit="0.0006" upper_limit="0.0085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03434" lower_limit="0.0050" upper_limit="0.1631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB1: Cycle 1 Day 1, Post dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03384" lower_limit="0.0059" upper_limit="0.1365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01926" lower_limit="0.0139" upper_limit="0.0579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01978" lower_limit="0.0111" upper_limit="0.0887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RHEB: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02719" lower_limit="0.0075" upper_limit="0.2452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RHEB: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02287" lower_limit="0.0078" upper_limit="0.1474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RHEB: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01810" lower_limit="0.0110" upper_limit="0.0377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RHEB: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01835" lower_limit="0.0107" upper_limit="0.0355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RPA1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05178" lower_limit="0.0097" upper_limit="0.1037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RPA1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05041" lower_limit="0.0091" upper_limit="0.0897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RPA1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05348" lower_limit="0.0262" upper_limit="0.1692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RPA1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05547" lower_limit="0.0261" upper_limit="0.1925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMAD1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00858" lower_limit="0.0001" upper_limit="0.1380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMAD1: Cycle 1 Day 1, Post-dose (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01116" lower_limit="0.0003" upper_limit="0.1996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMAD1: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00167" lower_limit="0.0004" upper_limit="0.0377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMAD1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00197" lower_limit="0.0004" upper_limit="0.0552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYK: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06101" lower_limit="0.0297" upper_limit="0.1445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYK: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05995" lower_limit="0.0256" upper_limit="0.1346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYK: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04237" lower_limit="0.0123" upper_limit="0.0918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYK: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04603" lower_limit="0.0166" upper_limit="0.0979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TCF3: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09144" lower_limit="0.0121" upper_limit="0.5337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TCF3: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07770" lower_limit="0.0138" upper_limit="0.4363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TCF3: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04216" lower_limit="0.0119" upper_limit="0.1552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TCF3: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05154" lower_limit="0.0126" upper_limit="0.2377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00465" lower_limit="0.0004" upper_limit="0.0335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00330" lower_limit="0.0004" upper_limit="0.0262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00376" lower_limit="0.0011" upper_limit="0.0230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00262" lower_limit="0.0009" upper_limit="0.0170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05412" lower_limit="0.0013" upper_limit="0.3051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04778" lower_limit="0.0020" upper_limit="0.2639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03196" lower_limit="0.0085" upper_limit="0.0892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02741" lower_limit="0.0052" upper_limit="0.0826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53BP1: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00386" lower_limit="0.0005" upper_limit="0.0233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53BP1: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00373" lower_limit="0.0005" upper_limit="0.0214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53BP1: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00205" lower_limit="0.0009" upper_limit="0.0070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53BP1: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00182" lower_limit="0.0008" upper_limit="0.0098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VDAC3: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03899" lower_limit="0.0095" upper_limit="0.1133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VDAC3: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03701" lower_limit="0.0114" upper_limit="0.1126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VDAC3: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03748" lower_limit="0.0192" upper_limit="0.0671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VDAC3: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03621" lower_limit="0.0189" upper_limit="0.0689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VPREB1: Cycle 1 Day 1, Baseline (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08210" lower_limit="0.0004" upper_limit="1.7113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VPREB1: Cycle 1 Day 1, Post-dose (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08593" lower_limit="0.0001" upper_limit="1.8106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VPREB1: Cycle 1 Day 15, 0 hours (n=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00472" lower_limit="0.0003" upper_limit="0.3317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VPREB1: Cycle 1 Day 15, Post-dose (n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00332" lower_limit="0.0003" upper_limit="0.4981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC2: Cycle 1 Day 1, Baseline (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00260" lower_limit="0.0002" upper_limit="0.0230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC2: Cycle 1 Day 1, Post-dose (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00297" lower_limit="0.0003" upper_limit="0.0247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC2: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00125" lower_limit="0.0003" upper_limit="0.0119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC2: Cycle 1 Day 15, Post-dose (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00124" lower_limit="0.0003" upper_limit="0.0105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC3: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00213" lower_limit="0.0002" upper_limit="0.0143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC3: Cycle 1 Day 1, Post-dose (n=50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00205" lower_limit="0.0002" upper_limit="0.0127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC3: Cycle 1 Day 15, 0 hours (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00110" lower_limit="0.0003" upper_limit="0.0048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC3: Cycle 1 Day 15, Post-dose (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00103" lower_limit="0.0002" upper_limit="0.0065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC4: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00175" lower_limit="0.0004" upper_limit="0.0038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC4: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00183" lower_limit="0.0004" upper_limit="0.0043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC4: Cycle 1 Day 15, 0 hours (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00172" lower_limit="0.0004" upper_limit="0.0035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC4: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00179" lower_limit="0.0006" upper_limit="0.0038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC5: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22952" lower_limit="0.0881" upper_limit="0.5646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC5: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18735" lower_limit="0.1152" upper_limit="0.2920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC5: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17577" lower_limit="0.1040" upper_limit="0.2685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC6: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07688" lower_limit="0.0117" upper_limit="0.2100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC6: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06620" lower_limit="0.0109" upper_limit="0.1937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC6: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04898" lower_limit="0.0163" upper_limit="0.1503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC6: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04495" lower_limit="0.0126" upper_limit="0.1489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ZAP70: Cycle 1 Day 1, Baseline (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11022" lower_limit="0.0156" upper_limit="0.4971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ZAP70: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10939" lower_limit="0.0169" upper_limit="0.4442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ZAP70: Cycle 1 Day 15, 0 hours (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18066" lower_limit="0.0082" upper_limit="0.5237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ZAP70: Cycle 1 Day 15, Post-dose (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15080" lower_limit="0.0083" upper_limit="0.5991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>XRCC5: Cycle 1 Day 1, Post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22401" lower_limit="0.0842" upper_limit="0.5260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were assessed from informed consent up to 28 calendar days after the last administration of investigational product, or up to the end of treatment visit (whichever is later) and to resolution/Grade 1 for treatment related AEs, up to 2 years.</time_frame>
      <desc>Events of veno-occlusive disease were reported up to 2 years after first dose of therapy. An event may appear as both an AE &amp; SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant &amp; nonserious in another participant, or 1 participant may have experienced both a serious &amp; nonserious event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.2 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.2 mg/m^2 given in 2 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Day 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="E2">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.6 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.4 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="E3">
          <title>Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="E4">
          <title>Phase 1 - Expansion Phase: IV Inotuzumab Ozogamicin 1.8 mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
        <group group_id="E5">
          <title>Phase 2: IV Inotuzumab Ozogamicin 1.8mg/m^2</title>
          <description>IV inotuzumab ozogamicin 1.8 mg/m^2 given in 3 doses over a 28-day cycle (0.8 mg/m^2 on Day 1 and 0.5 mg/m^2 on Days 8 and 15) for a maximum of 6 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Venoocclusive liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Central nervous system neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Mucosal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Blood test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash morbilliform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI must remove any previously undisclosed Confidential Information (other than the Study results themselves) before public release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

